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Integration of pharmacogenetic principles as a core 
thread in the undergraduate pharmacy curriculum
Pharmacy Education, 2016; 16 (1)  64 - 66
KIMBERLY JAMIE1*, HANNAH BOWS1, JASON GILL2
Introduction
Pharmacogenetics/pharmacogenomics, that is the 
response to medicines based upon hereditary factors, has 
led to the prescription of medicines based on a patients’ 
genetic information, referred to as personalised medicine 
(Li-Wan-Po,  2012).  This has been identified as a key 
element of future pharmacy practice in the United 
Kingdom (UK) and elsewhere (El-Ibiary et al.,  2008). 
Research has identified that in order to fully prepare 
pharmacists for this type of practice, undergraduate 
pharmacy education,  and indeed on-going professional 
development, needs to focus on the principles and 
practices of this developing science (Jamie, 2013). In 
order to introduce students to the field, a series of 
lectures, workshops and practical-based laboratory 
classes focused on the principles and clinical implications 
of pharmacogenetics/pharmacogenomics were delivered 
as an integrated theme within our integrated Masters of 
Pharmacy (MPharm) undergraduate course (Husband et 
al., 2014).
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Abstract
Introduction: Pharmacy education needs to focus on pharmacogenetics/pharmacogenomics as a key area in future 
pharmacy practice. 
Module Description: A series of science-focused lectures, including one on the ethical, legal and social implications 
(ELSI) of pharmacogenetics/pharmacogenomics, and laboratory practical sessions were delivered to first year students. 
Laboratory sessions were conducted to isolate genetic material from class participants, identify three variant genotypes 
within this population and demonstrated the implications of this genetic diversity for prescribing.
Assessment Method: Students submitted a report, structured as an academic paper,  documenting the study results and 
the implications of pharmacogenetics/pharmacogenomics for patient care. 
Evaluation: Focus groups comprising students evaluated the module as useful for furthering their understanding of 
pharmacogenetics/pharmacogenomics in practice. Of particular value was (1) receiving the module in year 1 as a 
fundamental part of the MPharm programme, (2) utilising laboratory methods and using students’ own genetic material 
and (3) integrating ELSI into the module. 
Future Plans: Pharmacogenetic implications will be built upon throughout the integrated curricula of the pharmacy 
course to further develop the student awareness of personalized medicines. Extended awareness of the clinical 
implications of pharmacogenetics/pharmacogenomics and associated ELSI has been built into a second year 
interprofessional education (IPE) workshop facilitated by clinical geneticists and involving both pharmacy and medical 
students. 
Keywords: ELSI, Hypertension, Pharmacogenetics, Pharmacogenomics, Pharmacy Education
Description of the Course and Assessments 
The course was delivered through a series of science-
focused lectures (3 hours) and practical-based laboratory 
practical sessions (3 x 4 hours) by a molecular 
pharmacologist (JG). The final lecture of the term (2 
hours) was delivered by a social scientist with a specialist 
interest in genetics (KJ) and focused on the ethical, legal 
social and professional implications of pharmacogenetics/
pharmacogenomics. Figure 1 shows the development and 
delivery of the teaching.
Students on the course were in the initial training year of 
their pharmacy education and had previously received 
lectures on the fundamental principles of biological, 
chemical and pharmaceutical sciences. They then 
received the lecture series focused on genetics and its 
application to clinical pharmacy. This was aimed at 
establishing a basic appreciation of the knowledge of the 
practical skills and fundamental principles of the field. 
The laboratory classes were delivered as three distinct but 
interrelated sessions and were structured around the 
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application of specific laboratory techniques,  with 
progressive outcomes relating to the clinical implications 
of pharmacogenetics/pharmacogenomics. 
Figure 1: Teaching and Assessment Flow
The initial session involved isolation of genetic material 
obtained from anonymised cheek swabs of class 
participants and support staff (after receiving their 
informed consent),  followed by amplification of the gene 
for Angiotensin Converting Enzyme (ACE), using a 
modification of the methodology previously described by 
Knoell and colleagues (Knoell et al.,  2009). The ACE 
gene was chosen based on its known polymorphic nature, 
its centrally important role in the pathophysiologic 
regulation of hypertension, and its clinical importance as 
a therapeutic target for disease management (Rigat et al., 
1990). This initial phase provided results indicative of the 
three expected ACE gene ‘versions’ (termed genotypic 
variants), with similar distribution profiles to that 
observed in the general population (Rigat et al., 1990).
The second phase of the laboratory study focused on 
translation of ACE gene expression to ACE protein levels 
detectable within the bloodstream, via a standard 
clinically-applicable quantitative assay; an Enzyme-
linked immunosorbent assay (ELISA). Although this 
ELISA was cost-effectively developed to detect a 
different protein this was not communicated to students 
and the results obtained were indicative of the ACE 
protein levels corresponding to gene expression (high, 
intermediate and low ACE protein levels). 
The third and final laboratory class contextualized the 
study by assessing the implications of the different ACE 
protein levels on response to the clinically applicable 
ACE inhibitor medicines,  via measurement of the amount 
of drug required to inhibit ACE activity representative of 
the three genotypes. 
The students then submitted a report documenting the 
study, including the results of the three phases of the 
experimental studies, and discussing their observations in 
light of the clinical scenario and implications of 
pharmacogenetics/pharmacogenomics on patient care. 
This report was structured into a format representative of 
a manuscript for submission to a scientific journal, 
relating a concept to clinic approach. This submission 
was then assessed against defined criteria, with the 
resulting mark forming a component of their grade for the 
first year of their undergraduate course.
Evaluation 
Evaluation was carried out through qualitative focus 
groups. 
The use of focus groups allowed us to gather rich data 
about students’ perspectives on the module content and 
delivery. Focus groups consisted of between 3-7 students 
with 21 students participating in total (from a total class 
size of 30 students) and were undertaken by HB, who is a 
qualitative social scientist and had not taught on the 
module. Focus group data highlighted three key strengths 
of the module.  
Firstly, the positioning of the module in the first year of 
the MPharm degree emphasized the importance of 
pharmacogenetics/pharmacogenomics to pharmacists’ 
work in the future. Teaching pharmacogenetics/
pharmacogenomics alongside content such as basic 
anatomy and chemistry positions the field as fundamental 
t o unde r s t and ing the pha rmacok ine t i c s and 
pharmacodynamics of medicines. 
Secondly,  students reported finding laboratory practical 
sessions more useful than classroom-based teaching. 
Using students own DNA to predict drug reactions was 
positively received and reported by students to better 
illuminate the application of pharmacogenetics/
pharmacogenomics than classroom-based teaching.  This 
pract ical way of teaching pharmacogenetics/
pharmacogenomics also speaks to students with diverse 
learning styles. 
Thirdly, the integration of social and ethical dimensions 
of pharmacogenetics/pharmacogenomics was highlighted 
by students as a particular positive. Many students 
reported not having thought extensively about the impact 
of pharmacogenetics/pharmacogenomic practice on 
patients before undertaking the module. The integration 
of social and ethical dimensions stimulated students to 
think critically and reflectively about their role in 
addressing social and ethical issues with their patients.
Future Plans 
Based on the feedback from these focus groups, we have 
made a number of plans for integrated delivery of 
pharmacogenetics/pharmacogenomics and personalized 
medicine into the MPharm programme, primarily through 
inclusion of indicative information embedded within 
lectures focused on therapeutics throughout the following 
three years of the course.  
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To contextualise the clinical importance of genetics to 
patient care and therapeutic disease management, and to 
further explore the ethical, legal and social implications 
(ELSI) therein, we have created a second year 
interprofessional education (IPE) workshop led by senior 
clinical geneticists. This IPE workshop involves 
collaborative working between pharmacy and medicine 
students, and is clinically case-based involving evaluation 
of genetic histories, disease pathophysiology, adapted 
therapeutic management, and clinical communication 
skills.
The pharmacogenetics/pharmacogenomics educational 
theme spirals throughout the MPharm programme then 
culminates in year 4 with a focus on the treatment of 
complex multi-factor diseases, particularly in oncology, 
for which personalized medicines are becoming standard 
treatment (Li-Wan-Po, 2012).
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